Searle is lagging the pharmaceutical sector. Its recovery might be just around the corner
The pharmaceutical company has had lackluster numbers in recent times. All that might be about to change
Despite deregulated prices, Searle swings to a loss
Price increases were not enough to compensate for increases in operating costs, despite a gross profit margin expansion
Drug price deregulation has come to Pakistan. What will this mean?
Companies can finally raise prices, which is likely to result in higher prices, but also likely to mean fewer shortages of essential drugs
Citi Pharma gets FDA nod to start exporting nutraceuticals to the United States
The pharmaceutical ingredients manufacturer enters the consumer-facing market in the US with a product the US regulator classifies as food, and not drugs
In the first quarter after deregulation, pharma sector revenue up by 25%
The increase in revenue is driven mostly by price increases as drug manufacturers can finally raise prices based on business need and rising costs instead of regulatory fiat
Ferozsons launches biologic to treat diabetes
Pharmaceutical company’s biotech subsidiary to launch the new product in one of Pakistan’s biggest therapeutic areas
Saudi investors exit Pakistan’s largest pharmacy chain. What happened and why?
From its origins as part of the Servis Group to multiple changes in ownership since its inception in 2005, Servaid has undergone an eventful two decades in existence
The magic pill for the pharma sector
Will the deregulation in drug pricing policy prove to be the long awaited cure for the pharmaceutical industry?
The mechanics behind the panadol shortage
Raids, hoarding and over regulating — You probably need a Panadol to figure out what’s going on
Where did all the Burnol go?
The household product is missing from pharmacies in Pakistan. But its brand recall still holds
Pharmaceuticals: how the locals are beating the multinationals
In a heavily regulated market, the local players have learned to live with the price rules the way they are, while the foreign players still seem to have hope that things will change
Pharmaceuticals in Pakistan: extracting whatever they can from the pie
Can the pharmaceutical sector ever be reformed? Kabeer Dawani and Asad Sayeed take a look at the sector’s pitfalls, and ways forward.
Can Hamdard thrive in the era of the millennial consumer?
It is an ad that relies on contrasts: a product as traditionally Pakistani as Hamdard’s Rooh Afza being consumed by non-Pakistanis in...
Is Treet Corporation Pakistan’s next big conglomerate?
Syed Sheharyar Ali is now the fourth generation of his family to be a major business owner in the region that is...
Pak pharma industry suffers from government’s shackles
A thriving sector in Pakistan’s economy, pharmaceuticals is a $3.2 billion industry, growing at 15% annually, while its exports now at $US200...